Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen, used on ...

Germany’s Merck KGaA is in advanced talks to acquire ... A SpringWorks spokesperson told Fierce Pharma the company "does not comment on market rumors or speculation.” The development comes ...

Germany’s Merck MRK0.81%increase; green up pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-1.98%decrease; red down pointing ...

The recent funding marks the first investment of U.S. pharma giant Merck Sharp & Dohme (MSD) in a health tech startup in Asia Pacific. (MSD is the brand that Merck uses to operate outside the U.S ...

Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

Among the so-called Big Pharma companies, Merck’s valuation is the lowest after Bristol Myers Squibb and Pfizer. The stock trades on a forward earnings multiple of just 10 times, below its five ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...